GSK's drug reduced the risk of death by 42% in a multiple myeloma study.
GlaxoSmithKline (GSK.US) reported that a study showed its drug belantamab mafodotin reduced the risk of death in patients with multiple myeloma at first relapse or after relapse by 42%.
The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone (BVd) versus daratumumab with bortezomib plus dexamethasone (DVd) as second-line or subsequent therapy for relapsed or refractory multiple myeloma.
The planned interim analysis (DREAMM-7) showed a statistically significant 42% reduction in the risk of death in patients receiving belantamab mafodotin versus the daratumumab-based comparator, with a median follow-up of 39.4 months.
GSK added that, although the median overall survival (mOS) had not been reached for either study group, the expected mOS was 84 months for BVd and 51 months for DVd, according to a statement.
The UK drugmaker also said the belantamab mafodotin combination showed a statistically significant advantage in the key secondary endpoint of minimal residual disease negativity.
The data were presented at the American Society of Hematology annual meeting in San Diego.